Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

BACKGROUND: Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to identify early humoral responses in genetically engineered mice (GEM) spontaneousl...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Capello, Michela, Cappello, Paola, Linty, Federica Caterina, Chiarle, Roberto, Sperduti, Isabella, Novarino, Anna, Salacone, Paola, Mandili, Giorgia, Naccarati, Alessio, Sacerdote, Carlotta, Beghelli, Stefania, Bersani, Samantha, Barbi, Stefano, Bassi, Claudio, Scarpa, Aldo, Nisticò, Paola, Giovarelli, Mirella, Vineis, Paolo, Milella, Michele, Novelli, Francesco
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2013
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3844582/
https://ncbi.nlm.nih.gov/pubmed/24010981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-67
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires